Comparing robotic and laparoscopic surgery for advanced gastric cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the clinical efficacy of robotic versus laparoscopic radical gastrectomy in patients with stage II and III gastric adenocarcinoma undergoing neoadjuvant treatment. It aims to determine which surgical approach offers better short-term clinical outcomes following neoadjuvant therapy. The study involves patients diagnosed with gastric cancer who have undergone preoperative staging and are deemed suitable for radical surgery after a multidisciplinary team discussion. The research is conducted at a single center in China, focusing on a population with a high incidence of gastric cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 18 years old ≤ 75 years old male or female;
2. The primary gastric lesion was diagnosed as gastric adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, Signet ring cell carcinoma, poorly differentiated adenocarcinoma) by endoscopic biopsy histopathology;
3. Before neoadjuvant treatment, the preoperative clinical staging was confirmed to be II and III (cT2N+M0 or cT3-4a/N+M0) through gastroscopy/ultrasound gastroscopy, enhanced CT/MR, or diagnostic laparoscopic exploration (based on AJCC-8th TNM tumor staging);
4. 2-4 cycles of neoadjuvant therapy (chemotherapy+/- targeted/immunotherapy, simple chemotherapy);
5. After new adjuvant treatment, radical Gastrectomy is feasible after MDT discussion;
6. Preoperative ECOG physical condition score of 0/1 or Karst score ≥ 70%;
7. Preoperative ASA score I-III;
8. The expected survival period exceeds 6 months;
9. Willing and able to comply with the research protocol;
10. Sign a written informed consent form before enrollment and be fully aware of the right to withdraw from this study at any time.

Exclusion Criteria:

1. Pregnant or lactating women;
2. Suffering from serious mental illness;
3. History of upper abdominal surgery (excluding history of laparoscopic cholecystectomy);
4. History of gastric surgery (excluding ESD/EMR for gastric cancer);
5. Moderate to severe renal insufficiency;
6. Organ transplant recipients receiving immunosuppressive therapy;
7. Have a history of other malignant diseases within 5 years;
8. Have a history of unstable angina or myocardial infarction within 6 months;
9. Have a history of cerebral infarction or cerebral hemorrhage within 6 months;
10. Have a history of continuous systemic corticosteroid therapy within one month;
11. Simultaneous surgical treatment of other diseases is required (excluding laparoscopic cholecystectomy);
12. Gastric cancer comorbidities (bleeding, perforation, obstruction) requiring emergency surgery;
13. Lung function test FEV1\<50% of expected value;
14. The patient has participated or is currently participating in other clinical studies (within 6 months).

Where it's running

• Department of Gastrointestinal Surgery, Qingdao University Affiliated Hospital
  Qingdao, Shandong, China Recruiting

Study contacts

• Study coordinator: Yanbing Zhou
• Email: zhouyanbing999@aliyun.com
• Phone: 13708971773

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using indocyanine green to improve lymph node removal in gastric cancer surgery

  This study is testing if a special dye called indocyanine green can help surgeons find and remove more lymph nodes during gastric cancer surgery.

  Recruiting Phase 3 Ukrainian Society of Clinical Oncology · Kyiv and 1 other locations · NCT06755554

• Combining two anticancer drugs for treating advanced gastric and gastroesophageal junction cancers

  This study is testing a new combination of two cancer drugs to see if they can help people with advanced HER2-positive gastric or gastroesophageal junction cancers feel better and live longer.

  Recruiting Phase 1 National Cancer Institute (NCI) · Houston, Texas · NCT06364410

• Combining Nivolumab with Standard Treatment for Advanced Stomach or Esophageal Cancer

  This study is testing if adding nivolumab to the usual treatments for advanced stomach or esophageal cancer can help patients live longer and feel better.

  Recruiting at 338 sites Phase 2/3 National Cancer Institute (NCI) · Little Rock, Arkansas and 377 other locations · NCT06203600

• Comparing two chemotherapy regimens for advanced HER2 negative gastric and esophageal cancer

  This study is testing if a new chemotherapy combination can help people with advanced HER2 negative stomach and esophageal cancer live longer compared to the standard treatment.

  Recruiting at 626 sites Phase 3 Alliance for Clinical Trials in Oncology · Birmingham, Alabama and 801 other locations · NCT05677490

• Personalized vaccine combined with pembrolizumab for advanced solid tumors

  This study is testing a new personalized cancer vaccine combined with pembrolizumab to see if it helps people with advanced solid tumors fight their cancer better.

  Recruiting Phase 1/2 Mayo Clinic · Jacksonville, Florida · NCT05269381

• Using pressurized aerosol chemotherapy to treat advanced abdominal cancers

  This study is testing a new way to deliver chemotherapy directly into the abdomen using a special aerosol spray to see if it helps people with advanced abdominal cancers feel better and have fewer side effects.

  Recruiting at 2 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT04329494

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.